表皮生长因子受体突变:gefitinib和erlotinib治疗非小细胞肺癌的靶点研究进展

Epidermal growth factor receptor mutation:The target of gefitinib and erlotinib to non-small cell lung cancer

Gefitinib和erlotinib是表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)类药物,是目前治疗非小细胞肺癌(NSCLC)的热点,已在多个临床试验中证实,东亚人群、女性、无吸烟史和腺癌患者有效,进一步的研究揭示癌症病人EGFR酪氨酸激酶区突变与对EGFR-TKI的敏感性密切相关。这些突变包括框架缺失、点突变等多种类型。本文综述了EGFR突变的研究现状和进展。

Gefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitors, which are the hot points of the treatment of non - small cell lung cancer. Several clinical trials have confirmed that they are effective to East Asian, female, never - smoking and adenocarcinoma. It is found that the EGFR mutations such as in - frame deletion and point mutation are correlated with clinical response to gefitinib and erlotinib. This summarv is on the research of EGFR mutations.